asked Her Majesty's Government:

Further to the Written Answers by Lord Darzi of Denham on 12 March (WA 235) and 13 March (WA 252) regarding representation of views on human cloning, how the relevant interests of members of the Human Fertilisation and Embryology Authority are recorded; and [HL2622]

Further to the Written Answers by Lord Darzi of Denham on 12 March (WA 235) and 13 March (WA 252) regarding representation of views on human cloning, what percentage of licensing decisions regarding nuclear transfer involved participation of (a) those known to be in favour of reproductive cloning, whether expressed publicly or confidentially; and (b) those opposed to the creation of human embryos for such research. [HL2623]

A register of Human Fertilisation and Embryology Authority (HFEA) members' interests is maintained and published in the HFEA's annual report. In making licence or policy decisions, as stated in my Answer of 12 March (WA 235), members of the HFEA are obliged to act within the regulatory parameters of the Human Fertilisation and Embryology Act 1990 and associated regulations.

The most recent edition of the report in the Library is 2004-05.

asked Her Majesty's Government:

Which therapies and clinical trials currently use adult stem cells; and which currently use embryonic stem cells. [HL2705]

The department does not collect detailed information on the number of therapies and clinical trials involving adult stem cells or embryonic stem cells.

The biological properties of stem cells have been exploited over the past several decades to develop a number of highly successful therapies using adult stem cells including bone marrow transplants, corneal transplants, related-donor cord blood transplants and skin grafting.

Embryonic stem cell trials are being planned for several conditions, including age-related macular degeneration, spinal injuries and diabetes.